VVM
RPTX

Versant Venture Management’s Repare Therapeutics RPTX Stock Holding History

Versant Venture Management’s Portfolio RPTX Stock Details RPTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,646,657
Closed -$4.66M – 9
2025
Q3 		$4.66M Hold
2,646,657
– – 2.19% 7
2025
Q2 		$3.68M Hold
2,646,657
– – 4.48% 5
2025
Q1 		$2.61M Hold
2,646,657
– – 4.33% 5
2024
Q4 		$3.47M Hold
2,646,657
– – 4% 5
2024
Q3 		$9.1M Hold
2,646,657
– – 14.32% 3
2024
Q2 		$8.73M Hold
2,646,657
– – 11.3% 4
2024
Q1 		$12.5M Hold
2,646,657
– – 12.09% 3
2023
Q4 		$19.3M Hold
2,646,657
– – 4.97% 3
2023
Q3 		$32M Hold
2,646,657
– – 17% 2
2023
Q2 		$28M Buy
+2,646,657
New +$27.3M 33.22% 1

Other funds holding RPTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
RC
Rangeley Capital New Canaan, Connecticut $103M AUM 77.32% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Versant Venture Management's RPTX Position: Q4 2025 in Review

Versant Venture Management sold out of Repare Therapeutics (RPTX) in Q4 2025, closing a stake of 2,646,657 shares — an estimated $4.66M sold.

Versant Venture Management first reported a position in RPTX in Q2 2023 and held it in 10 quarters. The position peaked at $32M in Q3 2023. 46 funds tracked by Wall St. Rank hold RPTX as of Q4 2025.

  • Versant Venture Management reported no remaining Repare Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Versant Venture Management sold 2,646,657 Repare Therapeutics shares in Q4 2025, an estimated $4.66M.
  • Versant Venture Management first reported a position in Repare Therapeutics in Q2 2023 and held it in 10 quarters.
  • Versant Venture Management's Repare Therapeutics position peaked at $32M in Q3 2023.
  • 46 funds tracked by Wall St. Rank held Repare Therapeutics as of Q4 2025.

Based on Versant Venture Management's 13F filing for Q4 2025, filed 12 Feb 2026.